The response to treatment according to the Residual Cancer Burden (RCB) score was not significantly related to the PIK3CA mutational status, as the frequency of PIK3CA mutations was similar in patients with pCR, RCB-I, RCB-II or RCB-III (p 0.454) (Table 6). This evidence concerns the gene PIK3CA and cancer.